Press Coverage and Latest Announcements
PRESS RELEASES
April 1, 2024
DELFI Diagnostics to Present at American Association for Cancer Research Annual Meeting
February 1, 2024
DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay
January 5, 2024
DELFI Diagnostics Appoints Susan Tousi as New Chief Executive Officer
December 13, 2023
DELFI Diagnostics Supports Proposed Legislation to Allow CMS to Review New Blood-Based Screening Tests for Lung Cancer
October 9, 2023
DELFI Diagnostics Launches FirstLook Lung, an Accessible, Accurate New Way to Enhance Lung Cancer Screening Through a Routine Blood Test
October 4, 2023
DELFI Diagnostics to Highlight Breakthrough Technology and Completed Clinical Study in Lung Cancer Detection
June 1, 2023
DELFI Diagnostics Hires David Morgenstern, PhD, as Vice President of Clinical Development
April 18, 2023
DELFI Diagnostics Presents Additional Promising Proof-of-Concept Data on its Monitoring Program at AACR 2023
February 23, 2023
Delfi Promotes Jenn Buechel to President and Chief Operating Officer
February 16, 2023
Delfi Hires Lee-Ann Smith-Freeman as Vice President of Legal
November 18, 2022
Positive Liver Cancer Detection Data Published in Cancer Discovery Shows Further Promise of Delfi’s AI Liquid Biopsy Platform
October 27, 2022
Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022
September 12, 2022
Delfi Diagnostics Selected as the Liquid Biopsy Partner for 4-IN-THE-LUNG-RUN: A Large-Scale European Lung Cancer Screening Study
August 23, 2022
Delfi Diagnostics Adds Finance and Market Access Leadership as it Prepares for Commercial Launch
July 18, 2022
Delfi Diagnostics Announces $225M Series B Financing
July 12, 2022
Jessica Meng Joins Delfi Diagnostics as Chief Commercial Officer
June 22, 2022
Delfi Diagnostics Appoints Jacob Van Naarden to its Board of Directors
May 17, 2022
Delfi Diagnostics Enters into Broad Research Agreement with Top U.S. Cancer Center
May 9, 2022
Delfi Diagnostics Initiates 15,000-Patient Prospective Lung Cancer Screening Trial
April 4, 2022
Delfi Researchers and Founders to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
March 30, 2022
Delfi Diagnostics Appoints Liz Homans to its Board of Directors
March 24, 2022
Delfi Diagnostics Adds Reimbursement, Regulatory Leaders to Management Team
October 21, 2021
Delfi Bolsters Leadership Team with Three Key Hires
October 7, 2021
Doug Schenkel Joins Delfi Diagnostics as Chief Financial Officer
August 20, 2021
Delfi Liquid Biopsy Shows Promise for Reducing Lung Cancer Deaths
June 23, 2021
Dr. Peter Bach Joins Delfi Diagnostics as Chief Medical Officer
March 31, 2021
Delfi Diagnostics Begins Enrollment for Prospective Lung Cancer Screening Trial Ahead of Planned Commercial Test
February 17, 2021
Industry Leaders Tara Maddala and Allison Ryan Join Delfi Diagnostics Leadership Team
January 12, 2021
Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers
MEDIA COVERAGE
Washington Post
April 16, 2024
A blood test to detect cancer? Some patients are using them already
Precision Medicine Online
April 10, 2024
Delfi Diagnostics' Liquid Biopsy Technology Shows Promise for Ovarian Cancer Screening
US News & World Report
April 10, 2024
AI May Bring a Better Blood Test for Ovarian Cancer
GenomeWeb
April 2, 2024
City of Hope and DELFI Diagnostics announce collaboration to improve lung cancer screening rates in underserved areas of Los Angeles
GenomeWeb
March 15, 2024
Johns Hopkins Team Debuts New Method for Genome-Wide Detection of Cancer-Linked Repeat Sequences
Medium
February 17, 2024
Victor Velculescu, DELFI Diagnostics — Founder Story
Pharmexec
February 1, 2024
DELFI Diagnostics Launches Assay That May Improve Monitoring of Cancer Treatment Response
FierceBiotech
February 1, 2024
Delfi launches cancer-monitoring blood test alongside Immunocore collab
MedTech Dive
January 9, 2024
Susan Tousi leaves Illumina to become CEO of liquid biopsy firm Delfi
Baltimore Business Journal
January 5, 2024
Baltimore biotech backed by more than $300M in funding names new CEO
BNN Breaking
January 4, 2024
Susan Tousi, Illumina CCO, to Helm Delfi Diagnostics as New CEO
STAT
January 4, 2024
Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi
Endpoints
January 4, 2024
Updated: Delfi Diagnostics hires Illumina’s chief commercial officer as next CEO
The Cancer Letter
November 17, 2023
Liquid biopsy cancer screening: We’ll need more than one size to fit all
MedTech Strategist
November 14, 2023
Can Delfi Diagnostics Fragmentomics be the key to detecting cancer early?
The Cancer Letter
October 13, 2023
Delfi Diagnostics Commercializes Blood Test for Lung Cancer Screening
Medical Device Network
October 10, 2023
DELFI Diagnostics introduces FirstLook Lung blood test
STAT
October 10, 2023
The Readout: Want a biotech buyout? Target cancer
MedTech Dive
October 9, 2023
Delfi launches lung cancer blood test based on DNA fragmentation
FierceBiotech
October 9, 2023
Delfi Diagnostics launches blood-based lung cancer screening test
STAT
October 9, 2023
Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies
BioTech TV
October 9, 2023
Delfi Diagnostics' team on launching the FirstLook Lung cancer blood screening test at #HLTH2023
360DX
September 26, 2023
BioAffinity Aims to Make Lung Cancer Test Available Nationally Following Pathology Lab Acquisition
STAT News
September 7, 2023
What a viral study criticizing cancer screening gets very, very wrong
GenomeWeb
August 22, 2023
DELFI Diagnostics Boost Lung Cancer Detection Power with Addition of Mutation Profiles DELFI Diagnostics Boost Lung Cancer Detection Power with Addition of Mutation Profiles
NCI Cancer Currents Blog
May 15, 2023
Can the New “Omics” on the Block Find Liver Cancer in Blood?
Baltimore Business Journal
May 12, 2023
Raising Baltimore’s Capital
STAT News
May 4, 2023
‘Are we better off with the information?’: Experts spar over the benefits of liquid biopsy to catch cancer
The Baltimore Sun
January 29, 2023
Baltimore researchers say AI could help reduce disparities, improve access in health care
Baltimore Business Journal
October 7, 2022
Leaders in Health Care 2022: Dr. Victor Velculescu, Delfi Diagnostics
Business Insider
September 6, 2022
21 Most Promising Health Tech Startups According to VCs 2022
San Francisco Business Times
August 30, 2022
Early-cancer detection company takes on billion-dollar competitors
Wall Street Journal
July 18, 2022
Delfi Diagnostics Gathers $225M for Cancer Blood Tests
GenomeWeb
May 17, 2022
Delfi Diagnostics, Memorial Sloan Kettering Partner to Advance Cancer Screening Technology
Precision Oncology News
May 9, 2022
Delfi Diagnostics Begins Second, Larger Prospective Lung Cancer Screening Trial
Fierce Biotech
March 7, 2022
Fierce Medtech’s 2021 Fierce 15
Fierce Biotech
August 20, 2021
Delfi Diagnostics’ AI-based blood test detects 80% of early-stage lung cancer cases, study finds
Stat News
June 23, 2021
Peter Bach, Industry Critic, Joins Company Aiming to Make Blood Tests to Detect Cancer
GenomeWeb
March 31, 2021
Delfi Diagnostics Starts Prospective Lung Cancer Screening Trial
FierceBiotech
January 13, 2021
Delfi Diagnostics Raises $100M for a New Approach to Screening Blood for Cancer
GenomeWeb
February 5, 2020
Methylation, Fragmentation Analyses Remain at Forefront of Early Detection Liquid Biopsy Development